



BIO MEDICA LABORATORIES PVT. LTD.

NOTICE IS HEREBY GIVEN THAT 7TH ANNUAL GENERAL MEETING OF THE MEMBERS OF BIO MEDICA LABORATORIES PRIVATE LIMITED("COMPANY") WILL BE HELD ON FRIDAY, 30TH SEPTEMBER, 2022 AT 11.30A.M IST AT THE REGISTERED OFFICE OF THE COMPANY AT PLOT NO. 254, SECTOR-F, SANWER ROAD, INDUSTRIAL AREA, INDORE - 452015 TO TRANSACT THE FOLLOWING ITEMS OF BUSINESS:

Ordinary Business:

ITEM NO. 1 -To consider and adopt the Annual Audited financial statements of the Company for the financial year ended March 31, 2022, consisting of the Balance Sheet, Statement of Profit and Loss and notes thereon, together with the reports of the Board of Directors and Auditors thereon.

By order of the Board of Directors

For Bio Medica Laboratories Private Limited

Pradeep Mehta
Director

DIN: 07254802
Date: 03.09.2022
Place: Indore



Registered Office:
PLOT NO. 254, SECTOR-F,
SANWER ROAD, INDUSTRIAL AREA,
INDORE - 452015

NOTES:

1. Notice is sent to all the shareholders, whose names appear in the Register of Members as on the date of notice.
2. *A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON POLL INSTEAD OF HERSELF/HIMSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY.* A person can act as proxy on behalf of members not exceeding 50 (Fifty) and holding in the aggregate not more than ten percent of the total share capital of the Company. Instrument of proxy, to be effective, must be deposited at the Registered Office of the Company not less than 48 hours before the commencement of the meeting.
3. A Proxy form is attached to the notice. Proxies submitted on behalf of the Companies, Societies, etc, must be supported by an appropriate resolution/authority, as applicable.
4. During the period beginning 24 hours before the time fixed for the commencement of Meeting and ending with the conclusion of the Meeting, a member would be entitled to inspect the proxies lodged at any time during the business hours of the Company.
5. Members / proxies should bring their attendance slip duly filled and signed for attending the meeting.
6. The documents referred to in the accompanying Notice and the Statements are open for inspection by the members at the registered office of the Company on all working days except Saturdays and Sundays (including public holidays), during business hours up to the date of this meeting.
7. Route map of the venue of this meeting is appended at the end of this notice.



Form No. MGT-11

Proxy form

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: U24230MP2015PTC034576

Name of the Company: BIO MEDICA LABORATORIES PRIVATE LIMITED

Registered Office: Plot-254, Sector-F Sanwer Road, Indore, Indore, Madhya Pradesh, India, 452015

Name of the member(s):

Registered address:

E-mail Id:

Folio No/ Client Id:

DP ID:

I/We being the member(s) of _____ shares, of the above named company, hereby appoint

1. Name:

Address:

E-mail Id:

Signature: _____, or failing him

as my / our proxy to attend and vote (on a poll) for me / us and on my / our behalf at the Annual General Meeting/ ~~Extraordinary General Meeting~~ of shareholders of the Company, to be held on Friday, the 30th day of September 2022, at 11:30 a.m. at Plot-254, Sector-F Sanwer Road, Indore, 452015 and at adjournment thereof in respect of such resolutions as are indicated below:

Sr. No.	Resolution
1	Ordinary resolution for adoption of annual accounts along with auditors' and directors' report for Financial Year 2021-22;

Signed this _____ day of _____ 2022

Affix Re.1/-
Revenue Stamp

Signature of Shareholder

Signature of Proxy holder(s)

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.



Attendance slip

BIO MEDICA LABORATORIES PRIVATE LIMITED

CIN: U24230MP2015PTC034576

Regd. Office: PLOT-254, SECTOR-F SANWER ROAD, NA, INDORE - 452015

I hereby record my presence at the Annual General Meeting of the Company held at Plot-254, Sector-F Sanwer Road, Indore, 452015, at 11:30 a.m. on Friday, the 30th day of September 2022.

_____	_____	_____
Full name of the Member (in block letters)	No. of shares held	Signature of member

Folio No: _____ DP ID No.* _____ Client ID No* _____


Applicable for member holding shares in dematerialized / electronic form.

_____	_____	_____
Full name of the Proxy (in block letters)	No. of shares	Signature of Proxy

NOTE: Member attending in person/proxy holder wishing to attend the meeting are requested to bring the attendance slip and hand it over at the entrance of the meeting place.



Route Map(with prominent landmark) of the venue of the Annual General Meeting is appended at the end of the Notice:



BIO MEDICA LABORATORIES PRIVATE LIMITED
REGD. OFF.: PLOT-254, SECTOR-F, SANWER ROAD INDORE, (M.P.) 452015

CIN:U24230MP2015PTC034576

DIRECTORS REPORT

Dear Members,

Your Directors have pleasure in presenting this Seventh Annual report on the affairs of the Company together with the Audited Statement of Accounts for the year ended on 31st March, 2022

1. Financial Summary or performance of the company:


(in Rs.)

PARTICULARS	2021-22	2020-21
1.NET SALES	212252005	129256742
2A.OTHER OPERATING INCOME	-	-
2B.OTHER INCOME	2118338	98494
3.TOTAL INCOME(1+2A+2B)	214370343	129355236
A) COST OF MATERIAL CONSUMED	148843972	92765283
B) PURCHASE OF STOCK IN TRADE	21159615	-
C) CHANGES IN INVENTORIES OF FINISHEDGOODS	(2888281)	(588125)
D) EMPLOYEE BENIFITS EXPENSES	17265519	14195892
G) OTHER EXPENSES	11059336	8572710
4. TOTAL EXPENSES	195440161	114945760
5. EBDIT(3-4+E+F)	18930182	14409476
6. INTEREST	7675628	5105978
7. DEPRECIATION	3281483	3298760
8.PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX(5-6-7)	7973070	6004738
9.CURRENT TAX & EARLIER TAX	2109125	1581247
10.MAT CREDIT RECEIVABLE	-	-
11.DEFERRED TAX	(26057)	31120
12.NET PROFIT AFTER TAX	5890002	4392371

For Bio-Medica Laboratories Pvt. Ltd.,

For Bio-Medica Laboratories Pvt. Ltd.,


Director.


Director.

*Previous year figures have been regrouped/ rearranged wherever necessary

2. Operations

The Company has reported Gross receipt of ₹ 212,252,005/- for the current year as compared to ₹ 129,256,742 /- in the previous year. The Net Profit for the year under review amounted to ₹ 58,90,002/- in the current year as compared to Profit of ₹ 43,92,371/- in the previous year.

3. Transfer to reserves

The Company proposes to carrying a total reserve & surplus of ₹ 2,25,35,294 /- including current year's Profit.

4. State of Company's Affairs and Future Outlook

Your directors are taking the best efforts so as to maximize the profits of the Company. During the year Company has made such investments which will give fruitful results in the year to come.

5. Disclosure regarding Issue of Equity Shares with Differential Rights: NA

6. Disclosure regarding issue of Employee Stock Options: NA.

7. Disclosure regarding issue of Sweat Equity Shares: NA

8. Dividend

Your directors do not recommend any dividend for financial period 2021-22.

9. Extract of Annual Return

For Bio-Medica Laboratories Pvt. Ltd. For Bio-Medica Laboratories Pvt. Ltd.,


Director.


Director.

The extract of Annual Return, in format MGT -9, for the Financial Year 2021-22 has been enclosed with this report.

10. Material Changes between the date of the Board report and end of financial year :-

There have been no material changes and commitments, if any, affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report.

11. Significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future:

During the year under review there has been no such significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.

12. Subsidiary Company:

As on March 31, 2022, the Company does not have any subsidiary.

13. Statutory Auditor & Audit Report:

M/s, Lunawat & Somani, Chartered Accountants, statutory auditors of the Company having Firm Registration Number 012609C hold office until the conclusion of the Eleventh Annual General Meeting subject to the ratification of the members at every general meeting. Further, the report of the Statutory Auditors alongwith notes to Schedules is enclosed to this report. The observations made in the Auditors' Report are self-explanatory and therefore do not call for any further comments.

14. Change in the nature/Name of business :-

There is no change in the nature or name of the business of the company

15. Corporate Social Responsibility:

The Company is not required to constitute a Corporate Social Responsibility Committee as it does not fall within purview of Section 135(1) of the Companies Act, 2013 and hence it is not required to formulate policy on corporate social responsibility.

16. Number of meeting of the Board:


During the year 2021-22, the Board of Directors met Six times viz. on 23/06/2021; 03/09/2021; 18/10/2021; 16/12/2021, 21/02/2022 and 31/03/2022.

17. Directors' Responsibility Statement:


Pursuant to the requirement under section 134(3) (C) of the Companies Act, 2013 with respect to Directors' Responsibility Statement, it is hereby confirmed that:

(i) In the preparation of the annual accounts for the financial year ended 31st March, 2022, the applicable accounting standards had been followed along with proper explanation relating to material departures;

For Bio-Medica Laboratories Pvt. Ltd.,


Director.

For Bio-Medica Laboratories Pvt. Ltd.,



Director.

(ii) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2022 and of the profit and loss of the company for that period;

(iii) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(iv) The directors had prepared the annual accounts on a going concern basis.

(vi) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

18. Declaration by Independent Directors

The Company was not required to appoint Independent Directors under Section 149(4) and Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 hence no declaration has been obtained.

19. Company's policy on directors' appointment and remuneration including criteria for determining qualifications, positive attributes, independence of a director and other matters provided under sub-section (3) of section 178;

The Company, being a Private Limited Company was not required to constitute a Nomination and Remuneration Committee under Section 178(1) of the Companies Act, 2013 and Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Stakeholders Relationship Committee under Section 178(5) of the Companies Act, 2013.

15. Particulars of loans, guarantees or investments under section 186:

During the year under review, the Company has not advanced any loans/ given guarantees/ made investments.

16. Particulars of Employee:

None of the employee has received remuneration exceeding the limit as stated in rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

17. Voluntary Revision of Financial Statements or Board's Report: NA

18. Statement in Respect of Adequacy of Internal Financial Control with Reference to the Financial Statements: NA

19. Secretarial Audit Report: NA

20. Re-appointment of Independent Auditor: NA

21. Corporate Social Responsibility (CSR) Policy: NA

22. Audit Committee: NA

23. Managerial remuneration:

During the year Company has paid amount of Rs. 48,00,000/- as Managerial Remuneration (Including Bonus) to the Directors of the company.

For Bio-Medica Laboratories Pvt. Ltd.,

For Bio-Medica Laboratories Pvt. Ltd.,

Director.

Director.

24. Particulars of contracts or arrangements with related parties: -

The particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act 2013 for the Financial Year 2021-22 in the prescribed format, AOC 2 has been enclosed with the report.

25. Details of Directors and Key Managerial Personnel

The Board consists of the following directors namely:-

DIN NO	NAME	DESIGNATION	DATE OF APPOINTMENT	DATE OF RESIGNATION
07254802	PRADEEP MEHTA	Director	14/08/2015	NA
03187420	MUKESH MEHTA	Director	14/08/2015	NA

26. Risk management policy:-

It may please be noted that as per the applicable requirement of Companies Act, 2013 a risk management policy of the Company is developed and implemented and Board reviews the same periodically for creating and protecting the Shareholder's value by minimizing threats or losses and to identify and provide a framework that enables future activities of a Company to take place in a consistent and controlled manner.

27. Details on conservation of energy, technology absorption, foreign exchange earnings and outgo:-

Information as per Section 134(3)(m) of the Companies Act, 2013, read with Companies (Accounts) Rules, 2014 and forming part of the Directors' Report to the members for the year ended 31st March, 2022.

- 1. Conservation of Energy:** - The activities carried out by the Company are not power intensive and the cost of the energy is insignificant. The Company is not utilizing alternate sources of energy.
- 2. Technical Absorption:-** The Company has not imported any technology during the year. There is no specific amount spent for research and development.

28. Statement Indicating the Manner in which Formal Annual Evaluation has been made by the Board of its own Performance, its Directors, and that of its Committees: NA**29. Nomination & Remuneration Committee Policy: NA****30. Disclosure on Establishment of a Vigil Mechanism: NA****31. Corporate Governance: NA****32. Formal evaluation by board of its own performance:-**

For Bio-Medica Laboratories Pvt. Ltd.,


Director.

For Bio-Medica Laboratories Pvt. Ltd.,


Director.

It may please be noted that the Statement in respect of Formal Evaluation by the Board of its own performance and that of its committees and individual directors is not applicable to the Company.

33. Internal Financial Controls

The company is having adequate internal financial controls with reference to the financial statements in terms of Section 134 (3) (q) of Companies Act, 2013 read with Rule 8 (5) (viii) of Companies (Accounts) Rules, 2014.

Acknowledgement:

Your Directors wish to place on record their sincere appreciation and gratitude for the valuable support and co-operation received from the Customers and Suppliers, various Financial Institutions, Banks, Government Authorities, Auditors and Shareholders during the year under review. Your Directors wish to place on record their deep sense of appreciation for the devoted services of the Executives, Staff and Workers of the Company for its success. Your Directors also thank the Central and State Governments, and other statutory authorities for their continued support.


For and on behalf of board of directors

Mukesh Mehta
Director
DIN: 03187420

Date: 03.09.2022

Place: Indore

For Bio-Medica Laboratories Pvt. Ltd.,



Director.

Pradeep Mehta
Director
DIN: 07254802

For Bio-Medica Laboratories Pvt. Ltd.,



Director.

FORM NO. AOC.2

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

1. Details of contracts or arrangements or transactions not at arm's length basis
 - (a) Name(s) of the related party and nature of relationship
 - (b) Nature of contracts/arrangements/transactions
 - (c) Duration of the contracts/arrangements/transactions
 - (d) Salient terms of the contracts or arrangements or transactions including the value, if any
 - (e) Justification for entering into such contracts or arrangements or transactions
 - (f) date(s) of approval by the Board
 - (g) Amount paid as advances, if any:
 - (h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188
2. Details of material contracts or arrangement or transactions at arm's length basis
 - (a) Name(s) of the related party and nature of relationship-**Mehta Sales Corporation, Akron Remedies, Hospara Health Care, Tara Mehta, Garima Mehta, Anju Mehta, Lokesh Mehta, Mukesh Mehta, Pradeep Mehta, Bio Medica Parenteral**
 - (b) Nature of contracts/arrangements/transactions - **Sales , Purchase, Rent, Salary, Interest**
 - (c) Duration of the contracts/arrangements/transactions- **FOR THE YEAR**
 - (d) Salient terms of the contracts or arrangements or transactions including the value, if any:
 - (e) Date(s) of approval by the Board, if any: - **31/03/2021**
 - (f) Amount paid as advances, if any: **NIL**

Form shall be signed by the persons who have signed the Board's report.

For and on behalf of Board of Directors
For Bio-Medica Laboratories Pvt. Ltd.,

For Bio-Medica Laboratories Pvt. Ltd.,

Mukesh Mehta
Director
DIN: 03187420


Director.

Pradeep Mehta
Director
DIN: 07254802


Director.

FORM NO. MGT 9
EXTRACT OF ANNUAL RETURN
As on financial year ended on 31.03.2022

Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014.

I. REGISTRATION & OTHER DETAILS:		
1	CIN	U24230MP2015PTC034576
2	Registration Date	14TH AUGUST 2015
3	Name of the Company	BIO MEDICA LABORATORIES PRIVATE LIMITED
4	Category/Sub-category of the Company	COMPANY LIMITED BY SHARE INDIAN NON-GOVERNMENT COMPANY
5	Address of the Registered office & contact details	PLOT-254, SECTOR-F SANWER ROAD INDORE M.P. 452015
6	Whether listed company	NO
7	Name, Address & contact details of the Registrar & Transfer Agent, if any.	Not Applicable


II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY			
(All the business activities contributing 10 % or more of the total turnover of the company shall be stated)			
S. No.	Name and Description of main products / services	NIC Code of the Product/service	% to total turnover of the company
1	MANUFACTURE OF PHARMACEUTICALS, MEDICINE CHEMICAL BOTANICAL PRODUCTS	2100	100
2			

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES					
SN	Name and address of the Company	CIN/GLN	Holding/ Subsidiary/ Associate	% of shares held	Applicable Section
1					
2					
3					

IV. SHARE HOLDING PATTERN									
(Equity share capital breakup as percentage of total equity)									
(i) Category-wise Share Holding									
Category of Shareholders	No. of Shares held at the beginning of the year [As on 01-April-2021]				No. of Shares held at the end of the year [As on 31-March-2022]				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual/ HUF		100,000	100,000	100.00%		100,000	100,000	100.00%	0.00%
b) Central Govt.			-	0.00%			-	0.00%	0.00%
c) State Govt(s)			-	0.00%			-	0.00%	0.00%
d) Bodies Corp.			-	0.00%			-	0.00%	0.00%
e) Banks / FI			-	0.00%			-	0.00%	0.00%
f) Any other			-	0.00%			-	0.00%	0.00%
Sub Total (A) (1)	-	100,000	100,000	100.00%	-	100,000	100,000	100.00%	0.00%
(2) Foreign									
a) NRI Individuals			-	0.00%			-	0.00%	0.00%
b) Other Individuals			-	0.00%			-	0.00%	0.00%

For Bio-Medica Laboratories Pvt. Ltd.,


Director.


Director.

c) Bodies Corp.			-	0.00%			-	0.00%	0.00%
d) Any other			-	0.00%			-	0.00%	0.00%
Sub Total (A) (Z)	-	-	-	0.00%	-	-	-	0.00%	0.00%
TOTAL (A)	-	100,000	100,000	100.00%	-	100,000	100,000	100.00%	0.00%
B. Public Shareholding									
1. Institutions									
a) Mutual Funds			-	0.00%			-	0.00%	0.00%
b) Banks / FI			-	0.00%			-	0.00%	0.00%
c) Central Govt			-	0.00%			-	0.00%	0.00%
d) State Govt(s)			-	0.00%			-	0.00%	0.00%
e) Venture Capital Funds			-	0.00%			-	0.00%	0.00%
f) Insurance Companies			-	0.00%			-	0.00%	0.00%
g) FIs			-	0.00%			-	0.00%	0.00%
h) Foreign Venture Capital Funds			-	0.00%			-	0.00%	0.00%
i) Others (specify)			-	0.00%			-	0.00%	0.00%
Sub-total (B)(1):-	-	-	-	0.00%	-	-	-	0.00%	0.00%
2. Non-Institutions									
a) Bodies Corp.									
i) Indian			-	0.00%			-	0.00%	0.00%
ii) Overseas			-	0.00%			-	0.00%	0.00%
b) Individuals									
i) Individual shareholders holding nominal share capital upto Rs. 1 lakh			-	0.00%			-	0.00%	0.00%
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh			-	0.00%			-	0.00%	0.00%
c) Others (specify)									
Non Resident Indians			-	0.00%			-	0.00%	0.00%
Overseas Corporate Bodies			-	0.00%			-	0.00%	0.00%
Foreign Nationals			-	0.00%			-	0.00%	0.00%
Clearing Members			-	0.00%			-	0.00%	0.00%
Trusts			-	0.00%			-	0.00%	0.00%
Foreign Bodies - D R			-	0.00%			-	0.00%	0.00%
Sub-total (B)(2):-	-	-	-	0.00%	-	-	-	0.00%	0.00%
Total Public (B)	-	-	-	0.00%	-	-	-	0.00%	0.00%
C. Shares held by Custodian for GDRs & ADRs			-	0.00%				0.00%	0.00%
Grand Total (A+B+C)	-	100,000	100,000	100.00%	-	100,000	100,000	100.00%	0.00%

(ii) Shareholding of Promoter

SN	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	

For Bio-Medica Laboratories Pvt. Ltd.,

For Bio-Medica Laboratories Pvt. Ltd.,

[Signature]
Director.

[Signature]
Director.

1	PRADEEP MEHTA	50,000	50.00%		50,000	50.00%	0.00%
2	MUKESH MEHTA	50,000	50.00%		50,000	50.00%	0.00%
3			0.00%			0.00%	0.00%
4			0.00%			0.00%	0.00%

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

SN	Particulars	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
	At the beginning of the year			100,000	100.00%	100,000	100.00%
	Changes during the year		Transfer		0.00%	-	0.00%
					0.00%		0.00%
					0.00%		0.00%
	At the end of the year			100,000	100.00%	100,000	100.00%

(iv) Shareholding Pattern of top ten Shareholders

(Other than Directors, Promoters and Holders of GDRs and ADRs):

SN	For each of the Top 10 shareholders	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
1	Name						
	At the beginning of the year				0.00%		0.00%
	Changes during the year				0.00%		0.00%
	At the end of the year				0.00%		0.00%
2	Name						
	At the beginning of the year				0.00%		0.00%
	Changes during the year				0.00%		0.00%
	At the end of the year				0.00%		0.00%

(v) Shareholding of Directors and Key Managerial Personnel:

SN	Shareholding of each Directors and each Key Managerial Personnel	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
1	PRADEEP MEHTA						
	At the beginning of the year	01/04/2021		50,000	50.00%	50,000	50.00%
	Changes during the year				0.00%		0.00%
	At the end of the year	31/03/2022		50,000	50.00%	50,000	50.00%
2	MUKESH MEHTA						
	At the beginning of the year	01/04/2021		50,000	50.00%	50,000	50.00%
	Changes during the year				0.00%		0.00%
	At the end of the year	31/03/2022		50,000	50.00%	50,000	50.00%

V. INDEBTEDNESS


Indebtedness of the Company including interest outstanding/accrued but not due for payment.

(Amt. Rs./)

Particulars	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
(i) Principal Amount	40,353,202.00	18,829,914.00		59,183,116.00

For Bio-Medica Laboratories Pvt. Ltd.,
For Bio-Medica Laboratories Pvt. Ltd.,


Director.


Director.

i) Interest due but not paid		-		-
ii) Interest accrued but not due		-		-
Total (i+ii)	40,353,202.00	18,829,914.00	-	59,183,116.00
Change in indebtedness during the financial year				
* Addition	45,816,636.00	4,804,937.00		50,421,573.00
* Reduction		-		-
Net Change	45,816,636.00	4,804,937.00	-	50,421,573.00
Indebtedness at the end of the financial year				
i) Principal Amount	86,169,838.00	23,434,851.00		109,604,689.00
ii) Interest due but not paid		-		-
iii) Interest accrued but not due		-		-
Total (i+ii+iii)	86,169,838.00	23,434,851.00	-	109,604,689.00

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Statement of Managing Director, Whole time Director and Manager				
SN.	Particulars of Remuneration	Name of MD/WTD/ Manager		Total Amount
		Name	Mukesh Mehta	Pradeep Mehta
	Designation	Managing Director	Managing Director	
1	Gross salary			
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	24.00	24.00	48.00
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961			-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961			-
2	Stock Option			-
3	Sweat Equity			-
4	Commission			-
	- as % of profit			-
	- others, specify			-
5	Others, please specify - Bonus			-
	Total (A)	24.00	24.00	48.00
	Ceiling as per the Act			

B. Remuneration to other Directors

SN.	Particulars of Remuneration	Name of Directors		Total Amount (Rs/Lac)
1	Independent Directors			
	Fee for attending board committee			-
	Commission			-
	Others, please specify			-
	Total (1)			-
2	Other Non-Executive Directors			
	Fee for attending board committee			-
	Commission			-
	Others, please specify			-
	Total (2)			-
	Total (B)=(1+2) *			-
	Total Managerial Remuneration			48.00
	Overall Ceiling as per the Act			

C. Remuneration to Key Managerial Personnel other than MD/Manager/WTD

SN.	Particulars of Remuneration	Name of Key Managerial Personnel	Total
-----	-----------------------------	----------------------------------	-------

For Bio-Medica Laboratories Pvt. Ltd.,

For Bio-Medica Laboratories Pvt. Ltd.,

[Signature]
Director

[Signature]
Director

	Name				(Rs/Lac)
	Designation	CEO	CFO	CS	
1	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961				-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961				-
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961				-
2	Stock Option				-
3	Sweat Equity				-
	Commission				
4	- as % of profit				-
	- others, specify				-
5	Others, please specify				-
	Total	-	-	-	-

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority (RD / NCLT/ COURT)	Appeal made, if any (give Details)
A. COMPANY					
Penalty					
Punishment					
Compounding					
B. DIRECTORS					
Penalty					
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty					
Punishment					
Compounding					

Mukesh Mehta

Director

DIN: 03187420

For Bio-Medica Laboratories Pvt. Ltd.,

Mukesh
Director.

Pradeep Mehta

Director

DIN: 07254802

For Bio-Medica Laboratories Pvt. Ltd.,

Pradeep
Director.

BIO MEDICA LABORATORIES PRIVATE LIMITED
(Balance Sheet As on 31 March 2022)

(CIN:U24230MP2015PTC034576)

(Amount in Rupees)

Particulars		Note No.	As at 31 March, 2022	As at 31 March, 2021
A	EQUITY & LIABILITIES			
1	Shareholder's Funds	A	10000.00	10000.00
	(a) Share Capital	B	225352.94	166452.92
	(b) Reserves & Surplus		-	-
	(c) Money Received Against Share Warrant		-	-
2	Share Application Money Pending Allotment		-	-
3	Non-Current Liabilities	C	411992.39	255666.40
	(a) Long-Term Borrowings		-	-
	(b) Deferred Tax Liabilities (Net)		-	-
	(c) Other Long Term Liabilities		-	-
	(d) Long-Term Provisions		-	-
4	Current Liabilities	D	684054.50	377909.45
	(a) Short-Term Borrowings	E	361609.06	359719.56
	(b) Trade Payables	F	31351.78	28444.42
	(c) Other Current Liabilities	G	21091.25	15812.47
	(d) Short-Term Provisions		-	-
	TOTAL		1745451.92	1214005.22
B	ASSETS			
1	Non-Current Assets			
	(a) Property, Plants & Equipment and intangible Assets	H	709855.47	507454.22
	(i) Property, Plant and Equipment		-	-
	(ii) Intangible Assets		-	-
	(iii) Capital Work-in-Progress		-	-
	(iv) Intangible Assets Under Development		-	-
	(b) Non-Current Investments	I	2807.93	2547.36
	(c) Deferred Tax Assets (net)		7870.12	4340.12
	(d) Long-Term Loans And Advances		-	-
	(e) Other Non-Current Assets		-	-
2	Current Assets			
	(a) Current Investments	J	232764.70	296053.20
	(b) Inventories	K	544691.26	300399.76
	(c) Trade Receivables	L	152819.55	3670.16
	(d) Cash and Cash Equivalents	M	31114.65	3815.60
	(e) Short-Term Loans And Advances	N	63528.23	95724.80
	(f) Other Current Assets		-	-
	TOTAL		1745451.92	1214005.22
	a to o			
Significant Accounting Policies				

As per our report of even date

For Lunawat & Somani

Chartered Accountants

FRN: 012609C

CA Gaurav Lunawat

Partner

M. No. 805423

UDIN:22405423AWLWJG4337



For and on behalf of The Board of Directors

For Bio-Medica Laboratories Pvt. Ltd.,

Mukesh Mehta

Director

DIN: 03187420

For Bio-Medica Laboratories Pvt. Ltd.,

Pradeep Mehta

Director

DIN: 07254802

Director.

Place: Indore

Date: 03.09.22

BIO MEDICA LABORATORIES PRIVATE LIMITED
(Statement of Profit & loss for the year ended 31st March 2020)
(CIN:U24230NP2015PTC034576)

(Amount in Rs.hundreds)

Particulars	Note No.	As at 31 March, 2022	As at 31 March, 2021
A CONTINUING OPERATIONS	O	21,22,520.05	1292567.42
1 Revenue from Operations (Gross)	P	21,183.38	984.94
2 Other Income		21,43,703.43	1293552.36
3 Total Income (1 + 2)			0.00
4 Expenses:	Q	14,88,439.72	927652.83
(a) Cost of Materials Consumed		2,11,596.15	-
(b) Purchases of Stock-in-Trade	R	(28,882.81)	-5881.25
(c) Change in Inventories of Finished Goods			0.00
Work-in-Progress and Stock-in-Trade(Increase in Stock)	S	1,72,655.19	141958.92
(d) Employee Benefits Expenses	T	76,756.28	51059.78
(e) Finance Costs	H	32,814.83	32987.60
(f) Depreciation and Amortization Expense	U	1,10,593.36	85727.11
(g) Other Expenses		20,63,972.73	1233504.98
Total expenses			
5 Profit before exceptional and Extraordinary items and Tax	(3 - 4)	79,730.70	60047.38
6 Exceptional Items		-	-
7 Profit before extraordinary items and Tax (5-6)		79,730.70	60047.38
8 Extraordinary Items		-	-
9 Profit before Tax (7-8)		79,730.70	60047.38
10 Tax Expense:			
(1) Current Tax		21,091.25	15,812.47
(2) Deferred Tax		(260.57)	311.20
11 Profit(loss) for the period from continuing operations (7-8)		58,900.02	43,923.71
12 Profit(loss) from discontinuing operations		-	-
13 Tax expense of discontinuing operations		-	-
14 Profit(loss) from discontinuing operations (after tax) (xi + xiv)		-	-
15 Profit(loss) for the period (XI + XIV)		58,900.02	43,923.71
Earning Per Equity Share			
Basic (Face value of Re. 10 each)	(In Rs.)	58.90	43.92
Diluted (Face value of Re. 10 each)	(In Rs.)	58.90	43.92
Significant Accounting Policies	a to o		

The accompanying notes are an integral part of these financial statements

As per our report of even date

For Lunawat & Somani

Chartered Accountants

FRN: 012696C

CA Gaurav Lunawat

Partner

M. No.405423

UDIN:22405423AWLW304337

For and on behalf of The Board of Directors

For Bio-Medica Laboratories Pvt. Ltd.,

Mukesh Mehta

Director

DIN: 03187420

Mukesh
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

Pradeep Mehta

Director

DIN: 07254802

Pradeep
Director.

Date: 03.09.22

Place: Indore

BIO MEDICA LABORATORIES PRIVATE LIMITED
Notes Forming Part of Balance Sheet

Note - A

Share Capital	2021-22	2020-21
Particulars		
Authorised Capital (100000 Shares of 10 each)	10,000.00	10,000.00
Issued Subscribed & Paid Up Capital	-	-
(100000 equity share of Rs. 10 - each fully paidup)	10,000.00	10,000.00
Total	10,000.00	10,000.00

1) Reconciliation of the shares outstanding at the beginning and at the end of the reporting period:

Particulars	2021-22 No. of Shares	2020-21 No. of Shares
Equity shares at the beginning of the year	1,000.00	1,000.00
Issued during the period	-	-
Equity shares at the end of the year	1,000.00	1,000.00

2) Details of the shareholders holding more than 5% in a company

Particulars	2021-22 No. of Shares	2020-21 No. of Shares
Pradeep Mehta	500.00	500.00
Mukesh Mehta	500.00	500.00

3) Terms & Rights attached to equity shares

- a) The Company has only one class of equity shares having a par value of Rs.10/- each, fully paid up.
b) Each holder of equity share is entitled to one vote per share.
c) The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.
d) In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(4) Shareholding of Promoters & % of change during the Year

Share s held Promo ters at the end of the year	Figures as at the end of previous reporting period			Figures as at the end of previous reporting period		
	No. of Shares held	% of total shares	% Change	No. of Shares held	% of total shares	% Change
Pradeep Mehta	500.00	50.00	-	500.00	50.00	-
Mukesh Mehta	500.00	50.00	-	500.00	50.00	-

Note - B

Reserves & Surplus	2021-22	2020-21
Particulars		
Retained Earnings/ Surplus:		
Balance as per Last Financial Statement	1,66,452.92	1,22,529.21
Add: Profit/(Loss) During the Year	58,900.02	43,923.71
Total	2,25,352.94	1,66,452.92



For Bio-Medica Laboratories Pvt. Ltd.,

Mukesh
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

Director.

Note - C

Long Term Borrowings

Particulars	2021-22	2020-21
Secured Loan	4,11,992.39	2,55,666.80
From Banks (Term Loans)	-	-
From NBFCs	4,11,992.39	2,55,666.80
Total		

Terms & Conditions of Term Loans:

ICICI BANK (SANCTION 5.10 LAC)

Repayment :Repayable in 60 equal monthly installments of Rs 10777/- Each from May 2019.
 Security:Secured by Hypothecation of motor Vehicle acquired out of this loan and personal guarantee of Directors
 Rate of Interest :Interest @ 9.75% Per annum.

Kotak Bank (Sanction 30.00 Lac)

Repayment :Repayable in 60 equal monthly installments of Rs 63152/- Each from DEC 2019.
 Security:Secured by Hypothecation of plant & machinery acquired out of this loan and other fixed assets of the company and personal guarantee of directors.
 Rate of Interest :Interest @ 9.60% Per annum.

Kotak Bank (Sanction 35.00 Lac)

Repayment :Repayable in 60 equal monthly installments of Rs 60646/- (rephased) each from Jan 2020 .
 Security:Secured by Hypothecation of plant & machinery acquired out of this loan and other fixed assets of the company and personal guarantee of directors.
 Rate of Interest :Interest @ 9.60% Per annum.

Kotak Bank (Sanction 102.5 Lac)

Repayment :Repayable in 120 equal monthly installments of Rs 134889/- Each, started from DEC 2019.
 Security:Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.
 Rate of Interest :Interest @ 9.90% Per annum.

ICICI Bank loan (Sanction 3.90 Lac)

Repayment :Repayable in 36 equal monthly installments of Rs 12744/- Each from Sept. 2020.
 Security:Secured by Hypothecation/ Mortgage of motor Vehicle acquired out of this loan and personal guarantee of Directors
 Rate of Interest :Interest @ 10.70% Per annum.

Kotak Lap (Sanction 125.00 Lac)

Repayment :Repayable in 120 equal monthly installments of Rs 151660/- Each, started from FEB 2021.
 Security:Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.
 Rate of Interest :Interest @ 8% Per annum.

Kotak Machinery Loan (Sanction 30.00 Lac)

Repayment :Repayable in 36 equal monthly installments of Rs 95150/- Each, started from FEB 2021.
 Security:Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.
 Rate of Interest :Interest @ 8% Per annum.

8 Kotak MSME (Sanction 4882000)

Repayment :Repayable in 48 equal monthly installments of Rs 152984/- Each, started from August 2021 after moratorium of 12 Months.
 Security:Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.
 Rate of Interest :Interest @ 8% Per annum.

SIDBI Loan (Sanction Rs. 130000.00)

Repayment :Repayable in 1-17th installments of Rs 720000 and 18th installment of Rs 760000/- Each, plus interest due, started from Aug 2020
 Security:Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.
 Rate of Interest :Interest @5%PA



For Bio-Medica Laboratories Pvt. Ltd.,

[Signature]
 Director.

For Bio-Medica Laboratories Pvt. Ltd.,

Director.

SIDBI Loan (Sanction Rs. 70000.00)
 Repayment: Repayable in 1-24th installments of Rs 23000 and 30th installment of Rs 33000/- Each, plus interest (dec, started from March 22.
 Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.
 Rate of Interest: Interest @5%PA

Kotak Lap (Sanction 150000.00)
 Repayment: Repayable in 120 equal monthly installments of Rs 177271/- Each, started from Oct 2021.
 Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.
 Rate of Interest: Interest = Repo rate plus spread 3.4 i.e. 7.4 % pa

There is no default in repayment of any of the above loan. The Company has used the borrowings from banks and financial institutions for the specific purpose for which it was taken as at the reporting date.

Note - D

Short-Term Borrowings	2021-22	2020-21
Particulars		
Working Capital Loan: (Secured)		
From Banks	2,80,069.55	1,47,865.62
Other Loans from related party (Unsecured):	2,34,348.51	1,88,299.14
Current Maturity of Long Term Borrowings	1,69,636.44	41,744.69
Total	6,84,054.50	3,77,909.45

Working Capital Bank loan is repayable on demand and primarily secured by hypothecation of stock and book debt And by personal guarantee of directors, bearing interest @9.35% Per annum. Interest for Rs. 301340/- is paid during the year.

Loans repayable on demand being Working Capital facilities from Banks (both fund based and non-fund based) are secured by first part passu charge by way of hypothecation of stocks of finished goods, raw materials, chemicals, stores, other materials including those in transit, book debts both present and future and the charge on fixed assets of the company.

Other Loans are unsecured and repayable on demand and bearing interest @12 % Per annum.

Note - E

Trade Payables	2021-22	2020-21
Particulars		
Micro Small & Medium Enterprises	55,664.95	6,521.74
Others	3,05,944.11	3,53,197.82
Total	3,61,609.06	3,59,719.56

Disclosure of payable to vendors as defined under the "Micro, Small and Medium Enterprise Development Act, 2006" is based on the information available with the Company regarding the status of registration of such vendors under the said Act. In the opinion of the management, the impact of interest, if any, that may be payable in accordance with the provisions of the Act, is not expected to be material.

Trade Payables ageing schedule: As at 31st March, 2022

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	55,664.95	-	-	-	55,664.95
(ii) Others	3,05,944.11	500.47	692.00	-	3,05,944.11
(iii) Disputed dues- MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-

Trade Payables ageing schedule: As at 31st March, 2021

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	-	-	-	-	-
(iii) Disputed dues- MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-



For Bio-Medica Laboratories Pvt. Ltd.,

Handwritten signature
 Director.

For Bio-Medica Laboratories Pvt. Ltd.,

Director.

Note - F**Other Current Liabilities**

Particulars	2021-22	2020-21
Statutory Dues Payable	7,099.53	6,053.49
Advance from customers	11,706.16	5,785.07
Other Payables		
Creditors for Capital Goods	1,781.79	509.98
Creditors for Expenses	11,851.46	16,071.99
Total	11,351.78	18,411.53

Note - G**Short-Term Provisions**

Particulars	2021-22	2020-21
Provision for Income Tax	11,091.15	15,812.47
Total	11,091.15	15,812.47

Note - I**Deferred Tax (Asset)**

Particulars	2021-22	2020-21
As Per Last Financial Statements	2,547.36	2,858.56
Incremental Deferred Tax Asset on account of Tangible & Intangible Assets	260.52	(111.20)
Total	2,807.93	2,547.36

Note - J**Other Non-Current Assets**

Particulars	2021-22	2020-21
Security Deposits	2,870.12	4,140.12
Total	2,870.12	4,140.12

Note - K**Inventories**

Particulars	2021-22	2020-21
Raw Material	13,600.29	1,64,665.12
Work-in-Progress	2,115.61	4,612.40
Finished Goods	46,234.73	15,055.13
Packing Material	1,10,614.07	1,11,720.54
Total	2,52,764.70	2,96,053.20

Note - K**Trade Receivables**

Particulars	2021-22	2020-21
Outstanding for more than six months	2,809.75	8,574.61
Others	5,41,791.51	2,91,825.15
Total	5,44,601.26	3,00,399.76

Trade Receivables ageing schedule as at 31st March, 2022

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months to 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	5,41,791.51	-	58.41	1,340.12	1,001.22	5,44,601.26
(ii) Under Disputed	-	-	-	-	-	-
(iii) Disputed	-	-	-	-	-	-
(iv) Disputed	-	-	-	-	-	-



For Bio-Medica Laboratories Pvt. Ltd.,

Director.

For Bio-Medica Laboratories Pvt. Ltd.,

Director.

Trade Receivables ageing schedule as at 31st March, 2021

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 3 months	Months 3 to 12	13 to 24	25 to 36	More than 36 months	
OT Undisputed Trade receivables - considered good	2,01,825.15	3,054.3	2,915.58	524.24	1,400.50	3,00,399.76
(ii) Undisputed	-	-	-	-	-	-
(iii) Disputed	-	-	-	-	-	-
(iv) Disputed	-	-	-	-	-	-

Note - L

Cash and Cash Equivalents

Particulars	2021-22	2020-21
Cash-in-Hand	694.11	3,113.74
Balance in Bank Accounts: In Current Accounts	1,00,498.14	556.42
Deposit with bank held as Security against borrowing*	51,627.30	-
Total	1,52,819.55	3,670.16

*Lien marked fixed deposit receipts is provided to bank/financial institution as security against borrowings which is not available for use.

Note - M

Short-term Loans & Advances

Particulars	2021-22	2020-21
Advance to Suppliers	31,114.65	3,815.60
Total	31,114.65	3,815.60

Note - N

Other Current Assets

Particulars	2021-22	2020-21
Balance with Revenue Authorities (Advance Tax)	20,000.00	16,100.00
Balance with Revenue Authorities (TDS)	739.42	174.73
IT Refund Receivables AY 2021-22	258.85	-
Goods and Service Tax (Net)	42,529.96	79,450.07
Total	63,528.23	95,724.80

Note - O

Revenue From Operations

Particulars	2021-22	2020-21
Sale of Manufacturing Products (Net of Taxes)	19,04,794.98	-
Sale of Trading Goods (Net of Taxes)	2,17,725.07	12,92,567.42
Total	21,22,520.05	12,92,567.42

Note - P

Other Income

Particulars	2021-22	2020-21
Interest Income	1,884.25	20.35
Discount, Rebate & Rate Difference	5,736.40	964.59
Exchange Rate Difference	13,562.73	-
Total	21,183.38	984.94



For Bio-Medica Laboratories Pvt. Ltd.,

Mulshi
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

Director.

Note - U
Other Expenses

Particulars	2021-22	2020-21
Audit Fees	300.00	300.00
Bank Charges	507.99	231.79
Comission	10,000.00	7,975.00
Design Charges	775.00	621.00
Electricity Expenses	23,187.72	30,115.30
Excise and Entry Tax	1,338.79	4,809.00
Freight & Documentation Expenses	27,815.72	6,410.23
Gst Short Payment	-	8,675.29
Late Fees, Interest & Penalties	244.85	1,679.11
Insurance Expenses	4,372.56	4,275.58
Lease Rent & Factory License	1,079.78	2,280.00
Legal & Professional Expense	5,952.15	3,975.24
Miscellaneous Expenses	4,509.29	3,462.20
Manufacturing & Testing Expenses	776.44	444.05
Medical Expenses	-	3,350.00
Office & Factory Expenses	1,119.44	730.32
Power & Fuel	17,840.92	2,406.48
Printing & Stationary	492.82	894.95
Property tax	562.65	867.05
Professional Tax	-	25.00
Repair & Maintenance	6,844.88	2,011.44
Supervision Charges	1,200.00	-
Telephone Expenses	97.42	47.98
Travelling Expenses	1,253.34	140.13
Vehicle Expenses	321.60	-
Total	1,10,593.36	85,727.11

Note - U(1)

Particulars	2021-22	2020-21
Payment to Auditors		
As an Statutory Audit Fees	250.00	250.00
As Income Tax Consultancy	50.00	50.00
Total	300.00	300.00



For Bio-Medica Laboratories Pvt. Ltd.,

[Signature]
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

[Signature]
Director.